share_log

bluebird bio | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

bluebird bio | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

bluebird bio | S-8：員工福利計劃證券登記
美股SEC公告 ·  11/14 16:37

Moomoo AI 已提取核心訊息

On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.
On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.
2024年11月14日，總部位於特拉華州的生物技術公司bluebird bio, Inc.向證券交易委員會提交了Form S-8註冊聲明。此次申報旨在註冊額外1500萬股普通股，作爲公司2023年激勵獎計劃的一部分，經股東於2024年11月6日批准增加發行授權股數從520萬股增加到2020萬股。Form S-8申報引用了公司之前與2023計劃相關的註冊聲明內的信息。公司總裁兼首席執行官Andrew Obenshain以及其他高管和董事簽署了註冊聲明，表明符合1933年證券法的要求。
2024年11月14日，總部位於特拉華州的生物技術公司bluebird bio, Inc.向證券交易委員會提交了Form S-8註冊聲明。此次申報旨在註冊額外1500萬股普通股，作爲公司2023年激勵獎計劃的一部分，經股東於2024年11月6日批准增加發行授權股數從520萬股增加到2020萬股。Form S-8申報引用了公司之前與2023計劃相關的註冊聲明內的信息。公司總裁兼首席執行官Andrew Obenshain以及其他高管和董事簽署了註冊聲明，表明符合1933年證券法的要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間